Gold Fields to Buy Osisko Mining for $1.57 Billion — Update
By Ian Walker
Gold Fields is set to buy Osisko Mining for $1.57 billion, giving the South African company full control of the Windfall project in Canada.
Under the deal Gold fields is offering 4.90 Canadian dollars in cash for each Osisko share held. The price is a 67% premium to its closing price of 2.94 Canadian dollars on Friday.
"Over the past two years, beginning with our initial due diligence in 2022 and throughout our joint ownership of the Project since May 2023, we have developed a strong understanding of Windfall and its potential, and view it as the next long-life cornerstone asset in our portfolio," Gold Fields Chief Executive Mike Fraser said Monday.
Windfall is expected to produce around 300,000 ounces of gold a year at an all-in sustaining cost of $758 an ounce, Gold Fields said.
It added that environmental permitting for full-scale construction of the project is underway, with a new round of questions recently received from the Quebec Ministry of the Environment, and final approval expected in 2025.
The company said it expects the deal to close in the fourth quarter of this year.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 12, 2024 01:54 ET (05:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks